Skip to main content

Prescription Drug Price Transparency Advisory Committee public comments

Public comments

The agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing the negative economic impact of the rule on business.

Whether individuals submit comments in person at committee hearings or not, all individuals who wish to submit public comment are strongly encouraged to do so in writing via email to

Comments received
(newer on top)

​​Committee contact

Jesse Ellis O'Brien
Senior Policy Analyst
Oregon Division of Financial Regulation


Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how